Cycle Pharmaceuticals Pipeline

Metabolic

Indication Technology Partners Quality of life needs addressed Feasibility Development Bio-Equivalence
Studies
Safety/Efficacy
Studies
FDA
Review
FDA
Approval
Commercialised
by
Technical Improvments Specialized Services for patients
NITYR® Hereditary Tyrosinemia Type 1(HT-1) Oral Tablet Ease of use Stability Reduced Size 2017
Gaucher’s Disease Capsules Not Required 2021
Phenylketonuria (PKU) Oral Tablet & Powder for Solution Not Required 2022
Gaucher’s Disease Zydis® ODT Low dose treatment Ease of Use Not Required 2024
Fabry Disease Zydis® ODT Low dose treatment Ease of Use Not Required 2026

Neurology

Indication Technology Partners Quality of life needs addressed Feasibility Development Bio-Equivalence
Studies
Safety/Efficacy
Studies
FDA
Review
FDA
Approval
Commercialised
by
Technical Improvments Specialized Services for patients
Wilson's Disease Capsules Not Required 2021
Paediatric epilepsy Soluble Tablets Dose adjustment Ease of Use Not Required 2022
Huntington’s Disease Zydis® ODT Dysphagia Ease of Use Not Required 2023
Parkinson’s Disease Zydis® ODT Dysphagia Ease of Use Not Required 2024
Tardive Dyskinesia Zydis® ODT Dysphagia Ease of Use Not Required 2025
Huntington’s Disease TEPI® Transdermal 
Patch Avoids dysphagia Reduction of Side Effects Not Required 2025

Immunology

Indication Technology Partners Quality of life needs addressed Feasibility Development Bio-Equivalence
Studies
Safety/Efficacy
Studies
FDA
Review
FDA
Approval
Commercialised
by
Technical Improvments Specialized Services for patients
Hereditary Angioedema Pre-filled syringe Not Required 2021

Last updated: June 2021

Scroll to explore the table

PRODUCTS
TECHNOLOGY PARTNERSHIPS